190 related articles for article (PubMed ID: 38267627)
1. Inhibition of ADAM9 promotes the selective degradation of KRAS and sensitizes pancreatic cancers to chemotherapy.
Huang YK; Cheng WC; Kuo TT; Yang JC; Wu YC; Wu HH; Lo CC; Hsieh CY; Wong SC; Lu CH; Wu WL; Liu SJ; Li YC; Lin CC; Shen CN; Hung MC; Lin JT; Yeh CC; Sher YP
Nat Cancer; 2024 Mar; 5(3):400-419. PubMed ID: 38267627
[TBL] [Abstract][Full Text] [Related]
2. Moving Towards Dawn: KRas Signaling and Treatment in Pancreatic Ductal Adenocarcinoma.
Rajpurohit T; Bhattacharya S
Curr Mol Pharmacol; 2022; 15(7):904-928. PubMed ID: 35088684
[TBL] [Abstract][Full Text] [Related]
3. ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma.
Oria VO; Lopatta P; Schmitz T; Preca BT; Nyström A; Conrad C; Bartsch JW; Kulemann B; Hoeppner J; Maurer J; Bronsert P; Schilling O
Mol Oncol; 2019 Feb; 13(2):456-479. PubMed ID: 30556643
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment.
Long SA; Amparo AM; Goodhart G; Ahmad SA; Waters AM
Front Oncol; 2024; 14():1402128. PubMed ID: 38800401
[TBL] [Abstract][Full Text] [Related]
5. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
6. Tetrandrine synergizes with MAPK inhibitors in treating KRAS-mutant pancreatic ductal adenocarcinoma via collaboratively modulating the TRAIL-death receptor axis.
Tang S; Duan Y; Yuan T; Hu Y; Yuan L; Shen N; Fu Y; Pu C; Wang X; Xu J; Lan X; Zheng Y; Zhou Y; Zhu H; Ding J; Geng M; Huang M
Pharmacol Res; 2023 Nov; 197():106955. PubMed ID: 37820855
[TBL] [Abstract][Full Text] [Related]
7. Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1.
Yan H; Yu CC; Fine SA; Youssof AL; Yang YR; Yan J; Karg DC; Cheung EC; Friedman RA; Ying H; Chen EI; Luo J; Miao Y; Qiu W; Su GH
Oncogene; 2021 Dec; 40(50):6759-6771. PubMed ID: 34663879
[TBL] [Abstract][Full Text] [Related]
8. Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review).
Zhang J; Darman L; Hassan MS; Von Holzen U; Awasthi N
Oncol Rep; 2023 Nov; 50(5):. PubMed ID: 37800636
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
10. Pan-KRAS inhibitors suppress proliferation through feedback regulation in pancreatic ductal adenocarcinoma.
Wang CX; Wang TT; Zhang KD; Li MY; Shen QC; Lu SY; Zhang J
Acta Pharmacol Sin; 2022 Oct; 43(10):2696-2708. PubMed ID: 35352018
[TBL] [Abstract][Full Text] [Related]
11. Urokinase-Type Plasminogen Activator Receptor (uPAR) Cooperates with Mutated
Peng L; Li Y; Yao S; Gaedcke J; Baart VM; Sier CFM; Neesse A; Ellenrieder V; Bohnenberger H; Fuchs F; Kitz J; Ströbel P; Küffer S
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900379
[TBL] [Abstract][Full Text] [Related]
12. Extracellular lumican augments cytotoxicity of chemotherapy in pancreatic ductal adenocarcinoma cells via autophagy inhibition.
Li X; Roife D; Kang Y; Dai B; Pratt M; Fleming JB
Oncogene; 2016 Sep; 35(37):4881-90. PubMed ID: 26876211
[TBL] [Abstract][Full Text] [Related]
13. Synergistic blocking of RAS downstream signaling and epigenetic pathway in
Zhang X; Mao T; Xu H; Li S; Yue M; Ma J; Yao J; Wang Y; Zhang X; Ge W; Wang Y; Shentu D; Wang L
Aging (Albany NY); 2022 Apr; 14(8):3597-3606. PubMed ID: 35468095
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines.
Ma Y; Schulz B; Trakooljul N; Al Ammar M; Sekora A; Sender S; Hadlich F; Zechner D; Weiss FU; Lerch MM; Jaster R; Junghanss C; Murua Escobar H
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139627
[TBL] [Abstract][Full Text] [Related]
15. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
16. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis.
Zhou T; Xie Y; Hou X; Bai W; Li X; Liu Z; Man Q; Sun J; Fu D; Yan J; Zhang Z; Wang Y; Wang H; Jiang W; Gao S; Zhao T; Chang A; Wang X; Sun H; Zhang X; Yang S; Huang C; Hao J; Liu J
J Exp Clin Cancer Res; 2023 May; 42(1):111. PubMed ID: 37143164
[TBL] [Abstract][Full Text] [Related]
17. Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition.
Yan L; Tu B; Yao J; Gong J; Carugo A; Bristow CA; Wang Q; Zhu C; Dai B; Kang Y; Han L; Feng N; Jin Y; Fleming J; Heffernan TP; Yao W; Ying H
Cancer Res; 2021 Aug; 81(15):4054-4065. PubMed ID: 34117030
[TBL] [Abstract][Full Text] [Related]
18. Bioinformatics Data Mining Repurposes the JAK2 (Janus Kinase 2) Inhibitor Fedratinib for Treating Pancreatic Ductal Adenocarcinoma by Reversing the
Liu LW; Hsieh YY; Yang PM
J Pers Med; 2020 Sep; 10(3):. PubMed ID: 32947833
[TBL] [Abstract][Full Text] [Related]
19. A
Windon AL; Loaiza-Bonilla A; Jensen CE; Randall M; Morrissette JJD; Shroff SG
J Gastrointest Oncol; 2018 Feb; 9(1):1-10. PubMed ID: 29564165
[TBL] [Abstract][Full Text] [Related]
20. Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?
Gillson J; Ramaswamy Y; Singh G; Gorfe AA; Pavlakis N; Samra J; Mittal A; Sahni S
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32456277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
